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Objective: Autologous chondrocyte implantation is a cell-based treatment to repair articular cartilage
defects, relying on the availability of expanded (de-differentiated) chondrocytes. Unfortunately, the
expansion process causes several phenotypical changes, requiring re-establishment of the native chon-
drogenic phenotype to sustain proper repair. Among other proteins, transforming growth factor-b (TGFb)
is known to inﬂuence the chondrogenic re-differentiation of human articular chondrocytes (HACs) and
their matrix deposition. Thus we investigated the effects of TGFb-depletion during the expansion phase.
Design: HACs were isolated from articular cartilage and expanded in the canonical serum-supplemented
medium [fetal calf serum (FCS)] or in a chemically-deﬁned (CD) medium, with or without anti-TGFb
antibody administration. The re-differentiation potential of the cells was assessed by pellet cultures, gene
expression analysis and histology.
Results: Cell proliferation proceeded more rapidly in CD-medium than in FCS-medium; it was not
affected by the use of anti-TGFb antibody but was further increased by addition of exogenous TGFb1, via
increased p-Smad1/5/8. Conversely, in FCS-medium, addition of anti-TGFb antibody decreased both
proliferation and p-Smad1/5/8 level. Challenging either FCS- or CD-medium with anti-TGFb antibody
during expansion enhanced chondrogenesis in the subsequent pellet cultures. Moreover, TGFb-depletion
during expansion in CD-medium inhibited mRNA expression of hypertrophic markers, collagen type-X
(COL10) and matrix metalloproteinase-13 (MMP-13). Interestingly, the TGFb1 level detected by enzyme-
linked immunosorbent sandwich assay (ELISA) during cell expansion was correlated with COL10 mRNA
expression after re-differentiation.
Conclusion: TGFb-depletion during expansion improves the re-differentiation capacity of chondrocytes
and inhibits hypertrophy. These results indicate the importance of the expansion medium composition to
improve chondrogenic re-differentiation and to inhibit hypertrophy.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Cartilage lesions have a limited capacity for self-repair and can
induce osteoarthritis (OA). Autologous chondrocyte implantation
(ACI) was the ﬁrst application of cell therapy used to repair focal
cartilage lesions in humans1. Since only a small cartilage biopsy can
be harvested without causing donor site morbidity, chondrocytes
have to be expanded to obtain the high cell number needed.
During expansion, however, chondrocytes lose their chondrogenic: G.J.V.M. van Osch, Room Ee
Rotterdam, The Netherlands.
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nl (G.J.V.M. van Osch).
s Research Society International. Pphenotype in a process called de-differentiation2,3, accompanied by
a shift from collagen type-II (COL2) expression to collagen type-I
(COL1) expression4,5. To improve the quality of cartilage generated
by culture-expanded chondrocytes, a re-differentiation process is
required. Several studies were focused on clarifying the role of
growth factors, scaffolds and mechanical stimulation during chon-
drogenic re-differentiation6e13. However, a limited number of
studies investigated which combination of factors can better sustain
the proliferation and maintain the re-differentiation capacity of
human articular chondrocytes (HACs)5,14e18.
Transforming growth factor-b (TGFb) has a key role in chon-
drocyte proliferation, differentiation and ECM production19e21. The
main TGFb signaling route is through speciﬁc membrane receptors
(activin receptor-like kinase receptors, ALKs) and its intracellular
effectors, the Smadproteins22. It is known that TGFb administration isublished by Elsevier Ltd. All rights reserved.
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frame Smad2/3 signaling plays a key role to sustain COL2 deposition,
while Smad1/5/8 activation is clearly associated with terminal
differentiation and mineralization23,24. Although TGFb1 positively
regulates the expression of speciﬁc cartilage proteins during re-
differentiation, previous and more recent work has demonstrated
that chondrocyte exposure to TGFb1 during proliferative phase in
a chemically-deﬁned (CD) medium hinders the re-differentiation
potential of these cells5,18. In addition, it is known that osteoar-
thritic chondrocytes after the re-differentiation phase are prone to
produce hypertrophic cartilage25e27 and that TGFb is markedly
increased in the osteoarthritic joint, in comparison to a healthy
environment28,29. Thus, paradoxically, within the large population of
OA patients, potential ACI undertakers may provide autologous cells
thatmay have beenprimedby a pathological environment, in spite of
having being harvested fromahealthy site that represents the golden
standard for cell-based cartilage repair. Taken together these obser-
vations raise the question whether hypertrophy of OA-chondrocytes
post-re-differentiation can be minimized not only by avoiding the
addition of TGFb during the expansion, but also by inhibiting its
effects,whetherelicitedby thecells endogenously-produced factoror
by the factor molecules already present in the serum.
In summary, the aim of this study was to investigate the effects
of different culture conditions [using fetal calf serum (FCS)-based or
chemically-deﬁned (CD) media] to clarify the role of TGFb during
the expansion phase of HACs, to improve the priming and handling
of the chondrogenic potential of OA-chondrocytes in view of their
potential clinical application for cartilage repair.
Materials and methods
Isolation of human adult articular chondrocytes
Cartilage was collected from femoral condyles of three patients
undergoing total knee arthroplasty for OA (patients implicitly con-
sented to the use of tissue for scientiﬁc research after approval by the
Medical Ethical Committee of Erasmus MC, Rotterdam, The
Netherlands; protocol#MEC2004-322) and two patients undergoing
total knee arthroplasty for traumatic lesion butwithout evident signs
of OA (patients had signed informed consent approved by the Ethical
Committee of the San Martino Hospital, Genoa, Italy). Explants were
minced, washed with phosphate-buffer saline (PBS) and single
chondrocytes were released by digestionwith 2 mg/mL protease XIV
(SigmaeAldrich, St. Louis, MO, USA), followed by 1.5 mg/mL Colla-
genase B (Roche Diagnostics, Mannheim, Germany) in Coon’s
modiﬁed Ham’s-F12 (F12; Biochrom A.G., Berlin, Germany), 10% FCS,
50 mg/mL Gentamicin and 1.5 mg/mL Fungizone (all from Invitrogen,
Paisley, Scotland, UK) overnight at 37C. Released chondrocytes were
seeded at density of 4,000 cells/cm2 in F12þ10% FCS for 48 h to allow
attachment to the plastic.
Culture conditions during the expansion (de-differentiation)
After 48 h in F12þ 10% FCS, HACs fromOA-donors werewashed in
PBS to remove residual traces of serum and distributed into four
different expansion conditions: (1) F12þ10% FCS (FCS), (2) FCSþ anti-
TGFb, (3) CD-medium or (4) CD þ anti-TGFb. The CD-medium was
adopted from our previous report5,18. Brieﬂy, ascorbic acid (250 mM),
linoleic acid (4.5 mM), dexamethasone (10 nM), cholesterol (13 mM), N-
acetylcysteine (50 mM), apo- and holo-transferrin (25 mg/mL each),
sodiumselenite (30nM), sodiumpantothenate (17mM),biotin (33mM),
insulin (10 mg/mL), Epidermal Growth Factor (EGF; 10 ng/mL), Fibro-
blast Growth Factor-2 (FGF-2; 10 ng/mL), Platelet Derived Growth
Factor-BB (PDGF-BB; 10 ng/mL) and human albumin (1%) were added
to F12. A pan-speciﬁc anti-TGFb monoclonal antibody (#MAB1835,R&D Systems, Minneapolis, MN, USA) was used. Based on preliminary
test to determine the concentration of endogenously-produced TGFb
in CD- or FCS-medium (877  685 pg/ml and 695  263 pg/ml
respectively) and its concentration in 10% FCS-containingmedium not
in contactwith the cells (597 52pg/ml),we added 2.6 0.6mg/mLof
anti-TGFb antibody to FCSþ anti-TGFbmediumand 1.6 1.2 mg/mL to
CD þ anti-TGFbmedium.
Chondrocytes from non-OA-donors were used to investigate the
effect of the Smad pathways on proliferation. For this purpose, cells
were expanded in CD-medium with or without TGFb1 (10 ng/mL,
B&D Bioscience, Bedford, MA, USA) and Dorsomorphin [(DM),
4 mM; Biomol International] or SB505124 (SB, 4 mM; SigmaeAldrich,
St. Louis, MO, USA) were used to inhibit phosphorylation of Smad1/
5/8 or Smad2/3, respectively. SB and DM effective concentrations
demonstrated in preliminary tests not toxic for the cells and
Western Blot analysis displayed selective inhibition of Smad2/3 or
Smad1/5/8 phosphorylation [Fig. 4(A)].
Cells of three donors were allowed to proliferate in standard
conditions (5% CO2 at 37C) and media were renewed every 48 h.
Medium was harvested to determine TGFb1 concentration.
After expansion chondrocytes were trypsinized by 0.25%
Trypsineethylenediaminetetraacetic acid (EDTA) (Invitrogen) and
counted using a BürkereTürk chamber (VWR, Amsterdam, NL).
The proliferation rate was calculated as doublings/days.
Chondrocyte re-differentiation: pellet culture
After expansion in the different conditions chondrocytes of three
donorswere centrifuged to obtainﬁve pellets of 2.5105 cells/donor.
Pellet cultures were transferred in chondrogenic induction medium
(as previously reported23) for the following 3 weeks to assay their
re-differentiation capacity with mRNA (two pellets/donor) or
immunohistochemical analysis (three pellets/donor). Medium was
renewed 3 times/week.
Proliferation assay: MTT-test
Chondrocytes of non-OA origin (two donors) were plated in
24-wells plates at density of 4,000 cells/cm2 and at different time-
points the medium was replaced by 0.5 mL of F12 without FCS or
additional factors with 25 mL of thiazolyl blue tetrazolium bromide
(MTT; SigmaeAldrich) stock solution (5 mg/mL). After 4 h medium
was removed, the dye solubilized in absolute ethanol and absorbance
was measured at 570 nm with background subtraction at 670 nm.
TGFb endogenous production
After expansion in monolayer, we collected the conditioned
medium of the last 24 h (CM) from the different culture conditions to
measure TGFb1 levels with a commercially available enzyme-linked
immunosorbent sandwich assay (ELISA; R&D Systems). Samples
were ﬁrst activated with 1 N HCl and 1.2 NaOH/0.5 M HEPES.
Experiments were performed in biological duplicate for three
OA-donors. Non-conditioned CD- and FCS-medium were used as
controls. For comparison, conditionedmedium from chondrocytes of
two non-OA-donors (in biological triplicate) was measured.
Smads analysis: Western Blot
After expansion chondrocytes of two donors were harvested
usingM-PER Protein extraction reagent (Thermo Scientiﬁc, Rockford,
IL, USA) with 1% protease inhibitor (Complete inhibitor, Roche). Total
protein concentration was determined with BCA Assay kit (Pierce,
Rockford, IL, USA). For each sample, 8e15 mg of protein lysate was
subjected to 10% sodium dodecyl sulfate-polyacrylamide gel
Fig. 1. Proliferation rate and Smad expression of OAeHACs expanded in monolayer using different media. (A) Proliferation rate of OAeexpanded HAC in different expansion media
(n ¼ 3): medium containing 10% FCS (FCS), FCS þ anti-TGFb antibody (FCS þ anti-T), CD-medium and CD þ anti-TGFb antibody (CD þ anti-T) were used. (B) Smads expression proﬁle
after expansion: (B1) Representative blots of the Smads of interest after immunodetection; (B2) Quantiﬁcation of Smad expression and phosphorylation in the tested samples
(n ¼ 2). All data are mean  standard deviation (SD). *Statistically signiﬁcant difference with FCS-expanded cells (P < 0.05). #Statistically signiﬁcant difference with FCS þ anti-
TGFb-expanded cells (P < 0.05).
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ride (PVDF)membranes.Membraneswere blocked for 2h in0.1% tris/
tween buffer (TBS-T) containing 5% dry milk powder, washed in 0.1%
TBS-T and incubated overnight at 4C with anti-Smad2/3 (1:1000;Fig. 2. GAGs and COL2 analyses of OAeHACs expanded in different media and subsequentl
were expanded in 10% FCS with or without anti-TGFb antibody (FCS and FCS þ anti-TGFb) an
Pellets were stained with thionine to detect GAGs in the ECM and the stained area was quan
chondrogenic induction of pellet cultures. (B2) Sections of pellet cultures immunostained
different donors and in biological triplicate for each donor. All data are mean  SD. *Statisti
#Statistically signiﬁcant difference with cells expanded in CD-medium (P < 0.05). All pictuCell Signaling Technology, Leiden, The Netherlands), anti-p-Smad2
(1:1000; Cell Signaling Technology), anti-Smad1/5/8 (1:200; Santa
Cruz Biotechnology, Heidelberg, Germany), anti-p-Smad1/5/8
(1:1000; Cell Signaling Technology), or anti-a-tubulin (1:1000; Celly cultured in pellets in the identical chondrogenic medium for 3 weeks. Chondrocytes
d in CD-medium with or without anti-TGFb antibody (CD and CD þ anti-TGFb). (A1e2)
tiﬁed with Image J freeware (see Materials and methods). (B1) COL2 positive areas after
with anti-COL2 antibody. Images are representative of pellets collected from three
cally signiﬁcant difference with cells expanded in FCS-medium (*P < 0.05; **P < 0.01).
res were taken at the same magniﬁcation (40).
Fig. 3. Relative expression of chondrogenic and hypertrophic markers after chondrogenic re-differentiation in pellet cultures using OAeHACs expanded in different expansion
media (FCS, FCS þ anti-TGFb, CD, CD þ anti-TGFb). (A) Chondrogenic markers: mRNA expression of AGC and COL2 after chondrogenic re-differentiation. (B) Hypertrophic markers:
mRNA expression of COL10 and MMP-13 after chondrogenic re-differentiation. The data of mRNA levels display the results obtained from three different donors in biological
duplicate. The value of AGC, COL2, COL10 and MMP-13 mRNA expression of cells expanded in FCS- or CD-medium was set to 1 (cross-hatch threshold line). All data are mean  SD.
*Statistically signiﬁcant difference with cells expanded in FCS-medium (*P < 0.05; **P < 0.01). #Statistically signiﬁcant difference with cells expanded in CD-medium (#P < 0.05;
##P < 0.01).
Fig. 4. Effect of TGFb and Smad inhibition on the expansion and re-differentiation of non-OAeHACs. (A) Western Blot analysis after the expansion phase in different conditions.
Smad expression and phosphorylation were detected using speciﬁc primary antibodies. Images are representative of data collected from two different donors. (B) HACs were
expanded in different expansion conditions and proliferation rate was tested by MTT-test (see Materials and methods for details). CD-medium with or without 10 ng/ml TGFb1
(CD and CD þ TGF respectively) was used. Moreover, in the presence of TGFb1, DM (4 mM) or SB505124 (SB; 4 mM) were used to inhibit Smad1/5/8 or Smad2/3 phosphorylation,
respectively. All data are mean  SD. *Statistically signiﬁcant difference with CD-expanded cells (**P < 0.01). #Statistically signiﬁcant difference with CD þ TGF þ DM-expanded cells
(##P < 0.01). Analyses were performed in biological triplicate on two different donors. (C) Re-differentiation potential of HACs expanded in different expansion conditions. After
expansion, HACs were transferred in pellets culture for the following 3 weeks using identical chondrogenic medium. Messenger RNA analysis was used to evaluate the expression of
articular cartilage markers (COL2 and AGC) or of hypertrophy markers (COL10 and MMP-13). All data are mean  SD. aStatistically signiﬁcant difference with CD-expanded cells
(aP < 0.05, aaP < 0.01), bStatistically signiﬁcant difference with CD- and CD þ TGF-expanded cells (bP < 0.05), cStatistically signiﬁcant difference with CD þ TGF-expanded cells
(cP < 0.05).
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peroxidase (HPR)-linked secondary antibody (1:1000; Cell Signaling)
was added for 1 h at room temperature. The blots were visualized
with SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientiﬁc) according to manufacturer’s instruction. Exposure time:
1e10 s for Smad1/5/8, Smad2/3 and a-tubulin; 30e60 s to detect p-
Smad1/5/8; 15e18 min for p-Smad2. Quantitative densitometric
analysis was performed with National Institute of Health, Image J
freeware (release 1.44).
Evaluation of chondrogenic differentiation: realtime
quantitative mRNA analysis
To evaluate de-differentiation after in-vitro expansion and re-
differentiation after pellet culture, mRNA expression analysis was
performed. Monolayer cells were washed with PBS and treated on
ice with RLT lysis buffer (Qiagen GmbH, Hilden, Germany). Pellets
were manually homogenized in RNA-Bee (TEL-TEST, Friendswood,
TX, USA) and RNA was extracted by adding 20% chloroform. RNAs
from expansion and pellet cultures were puriﬁed with RNeasy
Micro Kits (Qiagen). 1 mg of total RNA was reverse-transcribed into
complementary DNA (cDNA) using RevertAid First Strand cDNA
synthesis Kit (MBI Fermentas, St. Leon-rot, Germany). Polymerase
chain reactions (PCRs) were performed with TaqMan Universal PCR
MasterMix (Applied Biosystems, Capelle a/d Ijssel, The Netherlands)
and an ABI PRISM 7000 apparatus. Primer pairs were used to
determine the transcript levels of COL1, COL2, COL10, aggrecan
(AGC), matrix metalloproteinase-13 (MMP-13) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) using the settings previously
reported30e32. GAPDH was compared with two other housekeeping
genes [18s RNA and hypoxanthine phosphoribosyltransferase-1
(HPRT1)] and found to have the best stability throughout the
conditions and samples (data not shown). Relative gene expression
was calculated by means of the 2DCt formula33. The analyses were
performed in biological duplicate samples of three different donors.
Re-differentiation capacity: histology
For histology pellets were ﬁxed in 4% formalin and parafﬁn-
embedded. At least two sections (6 mm) of each sample were
stainedwith Thionine to detect glycosaminoglycans (GAGs) andwith
immunohistochemistry to detect COL2. Antigen retrieval was per-
formed with 0.1% pronase (SigmaeAldrich) in PBS for 30 min fol-
lowed by 10 mg/mL hyaluronidase (SigmaeAldrich) in PBS for
30min. Then, sections were incubated 2 hwith primary antibody for
COL2 (II/II6B3; Developmental Studies Hybridoma Bank, University
of Iowa, Iowa City, IA, USA). Alkaline phosphatase-labeled secondary
antibody was used in combination with Neu Fuchsine substrate
(Chroma, Kongen, Germany) resulting in a red staining. An isotype
IgG1 monoclonal antibody was used as negative control. Thionine
and COL2 positive areas of sections of triplicate pellets for each
culture condition for three different OA-donors were analyzed by
two blinded and independent observers using the National Institute
of Health, Image J freeware (release 1.44).
Statistical analysis
Data were analyzed with PSAW statistics 18.0 (SPSS Inc., Chicago,
IL, USA). A mixed linear model was used for mRNA expression,
histological and ELISA data. For proliferation rate and MTT-test one-
way analysis of variance (ANOVA) with Bonferroni post hoc-test was
performed. Fischer’s exact test was applied to analyze the effect on
pellet shape. The values obtained from the different pellets orwells for
each donor, were statistically evaluated with the mixed linear model.
Conditionswere considered as ﬁxed parameter and donors as randomfactor. Moreover when necessary a log transformation was applied
before statistical analysis to approach normal data distribution. Before
the analysis, Gaussian distribution of data sets was conﬁrmed by both
KolmogoroveSmirnov test and ShapiroeWilk tests.
In all the cases P < 0.05 was considered statistically signiﬁcant.
Results
Serum-free medium and TGFb-depletion inﬂuence cell proliferation
CD-medium rapidly induced a ﬁbroblast-like phenotype in
chondrocytes in monolayer as previously reported5,18. This also
happened in FCS-medium-expanded chondrocytes, although to
a lesser extent. These morphological changes were maintained
even if anti-TGFb antibody was added (data not shown). Interest-
ingly, TGFb-depletion in FCS-medium (FCS þ anti-TGFb) clearly
decreased the proliferation rate compared to standard FCS-medium
(FCS). On the other hand, chondrocytes growing in CD-medium
displayed the highest proliferation rate and in this medium anti-
TGFb antibody administration (CD þ anti-TGFb) did not affect cell
growth [Fig. 1(A)]. The time needed to reach subconﬂuency was
different with different expansion media: in FCS-medium cells
needed 18.67  5.03 days to reach conﬂuence; in FCS þ anti-TGFb
medium 24.67  8.33 days, in CD-medium 12.67  1.15 days and in
CD þ anti-TGFb medium 13.00  1.73 days. Nonetheless the
number of cells harvested at subconﬂuency was not signiﬁcantly
different between the conditions, hence the total number of cell
was similar for all conditions.
Cell de-differentiation was evaluated by real time-PCR. As
expected, up-regulation of COL1 and down-regulation of COL2
mRNA levels were evidenced, but with no differences between the
different media (data not shown).
TGFb uses intracellular signaling via Smads. The amount of total
Smad1/5/8 and total Smad2/3 was higher in cells expanded in
CD-medium compared to FCS-medium. The phosphorylated forms
of Smad1/5/8 and Smad2 (p-Smad1/5/8 and p-Smad2) were also
higher expressed in cells expanded in CD-medium compared to
FCS-medium. Anti-TGFb antibody administration caused a decrease
in p-Smad1/5/8 level in FCS-medium but had no effect in
CD-medium. Total Smad2/3 was substantially unaltered in all
tested culture conditions. However, p-Smad2 level diminished
upon addition of an anti-TGFb antibody in both FCS- and
CD-medium [Fig. 1(B1e2)].
TGFb-depletion during expansion enhances chondrogenic potential
The re-differentiation potential of expanded chondrocytes was
evaluated by pellet culture. After chondrogenic induction, the area
of the pellet that positively stains for thionine-positive GAGs was
smaller if pellets were generated using cells expanded in FCS-
medium compared to CD-medium; these results keep in line with
previous data5. Interestingly, anti-TGFb antibody administration in
FCS-medium during expansion resulted in pellets with larger GAG-
positive area, comparable to the area in pellets from cells expanded
in CD-medium [Fig. 2(A), FCSþ anti-TGFb vs CD]. In addition, TGFb-
depletion during expansion in CD-medium further increased the
GAG-positive area [Fig. 2(A), CD þ anti-TGFb]. Moreover, COL2
immunostaining showed the same trend as thionine staining
[Fig. 2(B)]. Cells expanded in CD þ anti-TGFb formed pellets with
the largest COL2 positive areas (86.3  10.6%) and the largest GAG-
positive areas (83.7  4.9% of positive areas) in the matrix.
TGFb-depletion clearly enhanced AGC mRNA expression in
pellets of cells expanded in FCS-medium (1.54  0.66-fold with
respect to the unitary expression in mediumwithout the antibody),
while in CD-medium the effect was less evident (1.19  0.08-fold
Fig. 5. Secretion of endogenously-produced TGFb1 by OA and non-OAeHACs in monolayer and the relation with COL10 gene expression during re-differentiation. (A) Endogenous
TGFb1 production was quantiﬁed by ELISA immunoassay after the expansion phase using 24 h conditioned medium (CM). CM of chondrocytes from non-OA origin (non-OAeHACs) or
OA-chondrocytes (OAeHACs) were analyzed. *Statistically signiﬁcantly different compared to non-OAeHACs (**P< 0.01). Biological triplicate samples of two donors (non-OAeHACs) or
biological duplicate samples of three donors (OAeHACs) were use for the analysis. (B) Correlation between TGFb1 secretion in the expansion phase and COL10 mRNA levels after re-
differentiation. HACs from OA (square dots) and non-OA patients (circular dots) expanded in CD-medium as well as OA-chondrocytes expanded in CD þ anti-TGFbmedium (triangular
dots) were used for the analysis. R2 indicate coefﬁcient of determination of the logarithmic correlation (black line).
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medium [Fig. 3(A)]. In addition, COL2 was up-regulated in pellets
of cells expanded with anti-TGFb antibody administration to both
CD- or FCS-medium [3.52  2.21-fold and 1.76  0.93-fold
respectively; Fig. 3(A)].
Different expansion conditions did inﬂuence the morphology of
the pellets during chondrogenesis. Most pellets (72.2%) from cells
expanded in FCS-containingmedia had an irregular, “doughnut-like”
shape [Fig. 2, (panels A2andB2)]. On the contrary, all pellets fromCD-
expanded chondrocytes had a spherical shape (100%, P < 0.001
compared to FCS-conditions). TGFb-depletion during FCS-expansion
enhanced the number of spherical pellets compared to FCS-only
condition (44.4% vs 11.1%), albeit not statistically signiﬁcant.
TGFb-depletion during expansion down-regulated hypertrophy
after re-differentiation
The level of hypertrophy after re-differentiation was evaluated
by collagen type-X (COL10) and MMP-13 mRNA expression
[Fig. 3(B)]. COL10 expression was strongly down-regulated after
3 weeks in chondrogenic induction medium if anti-TGFb antibody
was added to CD- or FCS-expansion medium (0.20  0.16 and
0.54  0.25-fold respectively). Transcript expression for MMP-13
showed a similar down-regulation in cells expanded in FCS-
medium supplemented with anti-TGFb antibody (0.51  0.04-fold
compared to FCS-medium only) or in CD-medium supplemented
with anti-TGFb antibody (0.60  0.33-fold compared to
CD-medium only).
Smad activity: effect on proliferation and re-differentiation
To further investigate the relation between cell proliferation,
TGFb and Smad activity we expanded chondrocytes from non-OA-
donors in CD-medium. TGFb1-administration during CD-expansion
(CD þ TGF) enhanced both p-Smad2 and p-Smad1/5/8 [Fig. 4(A)]
and signiﬁcantly increased the proliferation rate compare to the
control (CD) [Fig. 4(B)]. Interestingly, DM selectively inhibited
Smad1/5/8 phosphorylation [Fig. 4(A)] and abolished the TGFb1-
induced increase in cell proliferation speed, resulting in a cell
growth comparable to the control (CD). SB505124 (SB) selectively
inhibited p-Smad2 [Fig. 4(A)] but did not signiﬁcantly inﬂuence cell
growth compared to the condition with TGFb1-only (CD þ TGF)
[Fig. 4(B)].The effects of Smad activity during expansion on
re-differentiation capacity were determined by mRNA analysis on
pellet cultures using identical chondrogenic medium for all
conditions [Fig. 4(C)]. TGFb1-administration during expansion
enhanced the levels of hypertrophic markers COL10 and MMP-13
after re-differentiation and down-regulated the expression of
chondrogenic markers COL2 and AGC [Fig. 4(C); CD þ TGF]. Cells
cultured in the presence of either SB or DM in the CD-mediumwith
TGFb1 during expansion had signiﬁcantly lower COL10mRNA levels
after re-differentiation than cells expanded in the same medium
without inhibitors, although the expression was still higher than
that of cells expanded in CD-medium alone.MMP-13was also lower
when culturedwith SB or DM, although statistical differences could
not be proven. The inhibition of COL2 and AGC mRNA expression
induced by the presence of TGFb1 during expansion was abolished
when SB or DM were added. AGC mRNA expression was even
signiﬁcantly higher in the presence of DM compared to the refer-
ence CD þ TGF condition.
Chondrocytes from non-OA-donors produce less TGFb1 than
OA-chondrocytes
Chondrocytes from OA-donors produced signiﬁcantly more
TGFb1 than chondrocytes from non-osteoarthritic joints, although
the three OA-donors showed large variation in the amount of
TGFb1 produced [Fig. 5(A)].
Interestingly, TGFb1 production during the expansion phasewas
strongly correlated with the increase in COL10 mRNA expression.
This correlation is logarithmic with a correlation coefﬁcient (R2) of
0.806, meaning that 80.6% of the effect on COL10 mRNA levels can
be explained by endogenous TGFb1 production [Fig. 5(B)]. No clear
correlation was found between TGFb1 secretion during prolifera-
tion and MMP-13 mRNA levels after re-differentiation (data not
shown).
Discussion
Articular cartilage displays a limited repair capacity after injuries
and often undergoes progressive degeneration34. Despite several
efforts to enhance cartilage repair, ﬁbrocartilage formation and
hypertrophy still represent frequent undesired outcomes after ACI
treatments35. Moreover, due to aging of the population, cell-based
cartilage resurfacing approaches have to deal not only with the
R. Narcisi et al. / Osteoarthritis and Cartilage 20 (2012) 1152e11601158traumatic lesions to be repaired, but also with the need to handle
autologous cells within a possibly compromised articular environ-
ment, if not markedly OA-primed. Knowledge and control of cell de-
differentiation and re-differentiation capacities are of paramount
value to drive proper repair. Several factors contribute to articular
cartilage development and maturation14,15,17,18,36e39 and TGFb-
family members are the key initiators of chondrogenesis40,41. Our
results showed for the ﬁrst time that inhibition of endogenous TGFb
production during in-vitro expansion of HACs enhanced their re-
differentiation capacity and inhibited hypertrophic maturation.
Moreover, the TGFb present in commonly used FCS-containing
expansion medium appeared to have a negative effect on the
chondrogenic potential of these cells.
The signaling pathways elicited by TGFb rely on the balance of
Smad1/5/8 and Smad2/3 activities during the various stages of
chondrogenesis. In the early stage, Smad1/5/8 signaling is
required for chondrocyte proliferation and survival42 and during
cartilage maturation TGFb/Smad2/3 pathway stimulates COL2 and
AGC deposition43,44. Finally, chondrocyte terminal differentiation
is stringently controlled by transcription factor Runx2 which
function depends on interaction with Smad145,46. During this
phase, Smad2/3 is able to inhibit Runx2 nuclear translocation,
thereby inhibiting terminal differentiation47,48. However, despite
the knowledge of the function of TGFb during chondrogenesis, its
role during the ex-vivo expansion of chondrocytes is less deﬁned.
Addition of TGFb to expansion medium has been described to
increase proliferation; 8,49,50 however the mechanisms involved
have not been elucidated. Our results demonstrated that TGFb-
depletion during expansion decreased the proliferation speed and
the levels of p-Smad1/5/8 of chondrocytes when expanded in
FCS-containing medium but not in CD-medium. To better
understand the effect of TGFb on cell proliferation during chon-
drocyte expansion, we cultured human chondrocytes in TGFb-
deprived CD-medium and showed that exogenous addition of
TGFb1 activated Smad1/5/8 and Smad2/3 routes (as recently
reported51), ultimately increasing chondrocytes proliferation
compared to non-treated cells (CD-only). Interestingly, only
inhibition of Smad1/5/8 phosphorylation correlated with reduced
proliferation rate. These ﬁndings conﬁrm that Smad1/5/8 intra-
cellular pathway displayed a key role to sustain proliferation.
Since both cell proliferation and the levels of p-Smad1/5/8 in
CD-medium were unaltered by addition of anti-TGFb antibody,
other factors appear to maintain Smad1/5/8 activity during
expansion in this setting. It is known that Bone Morphogenetic
Proteins can promote proliferation and activate Smad1/5/8
intracellular pathway42,52, making them interesting candidates
for further investigation.
Our results also demonstrate that the presence of TGFb during
expansion culture can inﬂuence subsequent re-differentiation
capacity of chondrocytes. The extra-cellular matrix of pellets
constituted with cells expanded in CD- or FCS-medium treated
with anti-TGFb antibody displayed a larger area of COL2 and
proteoglycans than the matrix of pellets from cells expanded
without anti-TGFb antibody. Other authors have also reported
altered re-differentiation capacity of HACs exposed to speciﬁc
growth factors during the expansion. Jacob et al. deduced that
addition of TGFb1 alone to FCS-containing medium during expan-
sion negatively affected the re-differentiation process (COL2mRNA
expression)8. This conﬁrms our hypothesis that TGFb1 during
chondrocyte proliferation is detrimental for re-differentiation.
Later, Barbero et al. have shown that cell expansion in medium
with 10% FCS, FGF-2, PDGF-BB and TGFb1, had beneﬁcial effects on
proliferation and re-differentiation compared to the conditionwith
10% FCS-only49. However the effect of each individual factor was
not assessed. Therefore it is not clear whether the positive effect onre-differentiation was TGFb1-dependent or caused by the presence
or the interaction with PDGF-BB and FGF-2. Our previous results
showed that expansion in a CD-medium containing EGF, PDGF-BB
and FGF-2 improved the chondrogenic differentiation potential of
cells compared to expansion in FCS-containing medium and sus-
tained the proliferative burst needed to obtain a sufﬁcient number
of cells to cope with cartilage repair needs5. Although the compo-
sition of our CD-medium resembles that of Barbero et al., except for
the presence of FCS and the slightly different growth factor
concentrations, addition of TGFb1 to the CD-medium during
proliferation resulted inworse re-differentiation. This suggests that
the interaction between TGFb1 and other growth or serum factors
during expansion is still unclear and needs to be further
investigated.
Hypertrophy and chondrocyte terminal differentiation represent
a common undesired outcome during chondrocyte
re-differentiation. Our results indicate for the ﬁrst time that admin-
istration of anti-TGFb antibody during the expansion phase does not
only enhance the level of chondrogenic markers but also represses
the development of hypertrophy, as indicated by down-regulation of
MMP-13 and COL10mRNA expression. Upon TGFb1 stimulation, both
the Smad2/3 and the Smad1/5/8 pathway participate to the onset of
hypertrophic maturation of expanded chondrocytes, since selective
inhibition of either pathway resulted in reduced expression of
markers of hypertrophy. Moreover, we demonstrated a relation
between TGFb1 production during the expansion phase and COL10
gene expression after re-differentiation. Interestingly, we also
showed that chondrocytes from OA-donors produced signiﬁcantly
more endogenous TGFb1 than chondrocytes from non-osteoarthritic
joints. It is interesting to underline that although the inter-individual
variability between the non-OA-donors was minimal, the TGFb1
endogenous production between the OA-donors can be very
different. We hypothesize that this large inter-donors variability
could be explained by differences in the severity of the pathology.
However, this high endogenous TGFb1 production of
OA-chondrocytes might indeed be the cause of the hypertrophy
detected in chondrogenically re-differentiated chondrocytes from
OA-donors27.
The expansion phase is an obligated step in several cell-based
tissue engineering approaches for the repair of focal lesions in the
articular cartilage. Our results focused on the importance of the
expansion medium composition to improve chondrogenic re-
differentiation and to inhibit hypertrophy of the cells. As
a whole, CD-medium represents a proper approach to sustain
proliferation and cartilage forming capacity of expanded chon-
drocytes, particularly if endogenous TGFb is blocked. In a clinical
scenario, if for any reason it is not possible to use a CD-medium,
serum deprival of endogenous TGFb or its immune-blockade,
could represent feasible procedures to improve chondrogenic re-
differentiation capacities of the cells during culturing proce-
dures for ACI approaches.Author contributions
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